Subgroups	6 months events/patients		6 months PFS rate(95% CI)
Age			
<70	51/277		72.6 (66,78)
>=70	13/59		75.8 (61.7,85.3)
Line of therapy			
1st L	34/249		81.6 (75,86.6)
2nd L	17/48		54.8 (38.6,68.3)
>=3rd L	18/39		41.8 (25.1,57.7)
Liver metastasis			
Yes	14/29		45.4 (25,63.8)
No	52/307		75.5 (69.4,80.5)
Brain metastasis			
Yes	15/49		65.3 (48.4,77.8)
No	49/287		74.3 (67.9,79.6)
Camrelizumab treatment cycles			
>=6 cycles	19/178		85.2 (77.7,90.4)
<6 cycles	47/158		58.7 (49.5,66.9)
Tumor stage			
IB–IIIA	7/43		80.8 (63,90.7)
IIIB–IV	55/293		71.8 (65.4,77.2)
HBV infection			
Yes	2/21		89.5 (64.1,97.3)
No	40/206		72.1 (63.8,78.8)

0 10 20 30 40 50 60 70 80 90 100
6 months PFS rate (%)

Figure S1 Subgroup analysis of 6-month PFS in NSCLC patients treated with camrelizumab. PFS, progression-free survival; CI, confidence interval; NSCLC, non-small cell lung cancer.

Table S1 COX regression analysis of PFS in patients treated with camrelizumab

Variables	Univariate analysis		Multivariate analysis	
	HR (95% CI)	P	HR (95% CI)	P
Camrelizumab treatment line				
First line	Ref			
Second line	3.12 (1.822–5.342)	<0.001	2.177 (1.238–3.828)	0.007
≥ Third line	5.074 (2.984–8.626)	<0.001	7.533 (4.308–13.172)	<0.001
Age				
<70 years	Ref			
≥70 years	1.226 (0.709–2.119)	0.467		
Sex				
Male	Ref			
Female	1.335 (0.829–2.152)	0.235		
Histology				
Adenocarcinoma	Ref			
Squamous cell carcinoma	1.027 (0.655–1.61)	0.908		
Other/unspecified	0.769 (0.187–3.167)	0.716		
Smoking status				
Never	Ref			
Current/former	0.855 (0.54–1.353)	0.504		
Brain metastasis				
No	Ref			
Yes	1.408 (0.803–2.469)	0.232		
Liver metastasis				
No	Ref			
Yes	2.958 (1.662–5.268)	<0.001	2.416 (1.27–4.595)	0.007
Baseline antibiotics				
No	Ref			
Yes	0.806 (0.371–1.75)	0.585		
Baseline steroids				
No	Ref			
Yes	0.871 (0.534–1.422)	0.581		
Tumor stage				
IB–IIIA	Ref			
IIIB–IV	1.515 (0.73–3.144)	0.265		
Duration of camrelizumab use				
<6 cycles	Ref			
≥6 cycles	0.253 (0.155–0.414)	<0.001	0.192 (0.114–0.325)	<0.001
Patterns of camrelizumab use				
Monotherapy	Ref			
Plus CT	0.365 (0.192–0.696)	0.002		
Plus anti-angiogenesis	0.731 (0.328–1.629)	0.444		
Plus CT + anti-angiogenesis	0.352 (0.163–0.762)	0.008		

PFS, progression-free survival; HR, hazard ratio; CI, confidence interval; CT, chemotherapy.